A Phase 1 interventional study of ACT-541468 (Formulation A) and ACT-541468 (Formulation B) in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objectives of this first-into-man study were to investigate the safety, tolerability and the pharmacokinetic profile of single oral doses of ACT-541468 in healthy male adults. Pharmacodynamic effects (through a battery of Central Nervous System tests) were also assessed.
The study consisted of ascending dose groups; each dose group was investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo). In addition, the study included a biocomparison part (dose group 2), an absolute bioavailability part (dose group 4), and a mass balance / metabolism part (dose group 3).
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key inclusion Criteria:
Key exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A)
Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
Drug: ACT-541468 (Formulation A) · Drug: ACT-541468 (Formulation B) · Drug: Placebo (Formulation A) · Drug: Placebo (Formulation B)
Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A) · Drug: 14C-labeled ACT-541468 · Drug: Placebo tracer
Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A) · Drug: 14C-labeled ACT-541468 · Drug: Placebo tracer
Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
Drug: ACT-541468 (Formulation A) · Drug: Placebo (Formulation A)
Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
Soft gelatin capsules for oral administration formulated at the strength of 25 mg
Hard capsules matching ACT-541468 Formulation A
Soft capsules matching ACT-541468 Formulation B
Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
Number of subjects with treatment-emergent adverse events and serious adverse events
Collection of any adverse event at each dose level
Time frame: Day 8
Maximum plasma concentration (Cmax) of ACT-541468
Cmax was directly derived from the observed plasma concentrations of ACT-541468 for each dose level
Time frame: From pre-dose up to 168 hours post-dose
Time to reach Cmax (tmax) of ACT-541468
tmax was directly derived from the observed plasma concentrations of ACT-541468 for each dose level
Time frame: From pre-dose up to 168 hours post-dose
Terminal half-life (t1/2) of ACT-541468
t1/2 was calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-541468, at each dose level
Time frame: From pre-dose up to 168 hours post-dose
Area under the plasma concentration-time curves [AUC(0-inf)] of ACT-541468
AUC(0-inf) is the area under the plasma concentration-time curves of ACT-541468, calculated from time 0 (pre-dose) to extrapolated infinite time, at each dose level
Time frame: From pre-dose up to 168 hours post-dose
Percentage of dose excreted in feces and urine
Percentage of oral dose of 14C-labeled ACT-541468 excreted in feces (FPE), urine (UPE) and both, as determined in the dose group 3
Time frame: From pre-dose up to 168 hours post-dose
Absolute bioavailability (F) of ACT-541468
Absolute bioavailability was determined for dose group 4 and defined as the ratio of AUC(0-inf) after oral administration of ACT-541468 and after intravenous infusion of 14C-labeled ACT-541468 (tracer)
Time frame: Up to 96 hours post-dose
Change from baseline in saccadic peak velocity (SPV)
Time frame: At baseline till 10 hours after study drug administration
Change from baseline in body sway
Time frame: At baseline till 10 hours after study drug administration
Change from baseline in adaptive tracking
Time frame: At baseline till 10 hours after study drug administration
Chnage from baseline in Bond and Lader visual analog scale (B&L VAS)l
Time frame: At baseline till 10 hours after study drug administration
Ran from Feb 2015 to primary completion in May 2015, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Idorsia Pharmaceuticals Ltd. →